Limestone County 9-year-old one step closer to getting kidney transplant
LIMESTONE COUNTY, Ala. (WHNT) — A 9-year-old from Limestone County is one step closer to finding a kidney donor.
Last month, News 19 introduced you to Ruger Ennis, a boy who only recently discovered that he was in stage 5 kidney failure and would need a kidney transplant.
After years of darkness the Hudson Memorial Bridge has new lights
Since our first interview, Ruger went through surgery, celebrated a birthday, and got two pieces of really good news.
Tuesday, Ruger and his mom, Haley Schrimsher, were all smiles as they Zoomed from their room at the Ronald McDonald House in Birmingham. They're excited because it's likely their last week in the hospital.
'Hopefully, he gets to come home, except for clinic visits, next Tuesday,' Schrimsher said.
Ruger underwent a successful surgery in May to prepare him to receive at-home dialysis. Now, he's almost ready to transition into the new routine.
HPD respond to incident on Water Stream Drive believed to be mental health crisis
'It's going to look like 12-hour days at first,' Schrimsher said. 'He'll get hooked on the machine at 5 o'clock and then he'll get off at 5 the next morning, and then when he goes back to school around that time it'll be around 7-hour days.'
Although it will be a rigorous dialysis schedule, being back at home will have its perks. Ruger gave a big 'thumbs up' to the idea of going back to school in the fall and seeing his friends and classmates.
Ruger is also healthy enough now to have a kidney transplant, once he finds a donor.
'The transplant coordinator said, 'Well, he's got yesses on everything, his labs look beautiful, he's ready for transplant,'' Schrimsher said.
He's been on the hunt for a donor for a few weeks now, but Schrimsher said the process has actually moved pretty quickly.
She said they have three potential donors, and that they'll do further blood testing in the next week.
'One of them is a Birmingham police officer, one of them works for a Christian-based nursing company, and the other one is a dialysis nurse at Vanderbilt,' Schrimsher said. 'So we're just hoping that one of them is the perfect match.'
If they can find that perfect match, Ruger could undergo a transplant by the end of the year. He said he hopes it will happen by Christmas!
Schrimsher said she's very hopeful that one of the potential donors will work out, but due to the complicated nature of organ donation, they aren't discouraging others from reaching out.
If you're interested in seeing if you could be a donor for Ruger, they encourage you to email LoveLikeRuger@yahoo.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
27 minutes ago
- Gizmodo
Bats Have Cancer-Fighting ‘Superpowers'—Here's What That Means for Humans
When you think of longevity in animals, chances are that the Greenland shark will immediately come up. After all, researchers estimate that the enigmatic animal can live for at least 250 years. It turns out, however, that bats also hold their own when it comes to lifespan, with some species living up to 25 years—equivalent to 180 human years—and they tend to do it cancer-free. Researchers from the University of Rochester (UR) have investigated anti-cancer 'superpowers,' as described in a UR statement, in four bat species: the little brown bat, the big brown bat, the cave nectar bat, and the Jamaican fruit bat. The results of their investigation could have important implications for treating cancer in humans. 'Longer lifespans with more cell divisions, and longer exposure to exo- [external] and endogenous [internal] stressors increase cancer incidence,' the researchers wrote in a study published last month in the journal Nature Communications. 'However, despite their exceptional lifespans, few to no tumors have been reported in long-lived wild and captive populations of bats.' Led by biologists Vera Gorbunova and Andrei Seluanov from the UR Department of Biology and Wilmot Cancer Institute, the team identified a number of biological defenses that help bats avoid the disease. For example, bats have a tumor-suppressor gene, called p53. Specifically, little brown bats carry two copies of the gene, and have high p53 activity, which can get rid of cancer cells during apoptosis, a biological process that eliminates unwanted cells. 'We hypothesize that some bat species have evolved enhanced p53 activity as an additional anti-cancer strategy, similar to elephants,' the researchers explained. Too much p53, though, runs the risk of killing too many cells. Clearly, bats are able to find the right apoptosis balance. Humans also have p53, but mutations in the gene—which disrupt its anti-cancer properties—exist in around 50% of human cancers. The researchers also analyzed the enzyme telomerase. In bats, the telomerase expression allows bat cells to multiply endlessly. That means they don't undergo replicative senescence: a feature that restricts cell proliferation to a certain number of divisions. Since, according to the study, senescence 'promotes age-related inflammation contributing to the aging process,' bats' lack thereof would seem to promote longevity. And while indefinite cell proliferation might sound like the perfect cancer hotbed, bats' high p53 activity can kill off any cancer cells. Furthermore, 'bats have unique immune systems which allows them to survive a wide range of deadly viruses, and many unique immune adaptations have been described in bats,' the researchers wrote. 'Most knowledge of the bat immune systems comes from studies of bat tolerance to viral infections deadly to humans. However, these or similar immune adaptations may also recognize and eliminate tumors,' as well as 'temper inflammation, which may have an anticancer effect.' Cells have to go through several steps, or 'oncogenic hits,' to become harmful cancerous cells. Surprisingly, the researchers also found that it only takes two hits for normal bat cells to become malignant, meaning bats aren't naturally resistant to cancer—they just have 'robust tumor-suppressor mechanisms,' as described in the statement. The team's findings carry important implications for treating cancer. Specifically, the study confirms that increased p53 activity—which is already targeted by some anti-cancer drugs—can eliminate or slow cancer growth. More broadly, their research is yet another example of scientists turning to nature for solutions to human challenges on all scales. Though the study focuses on bats, the ultimate aim is, always, finding a cure for cancer in humans.
Medscape
37 minutes ago
- Medscape
IRONMAN: Can PSA Guide Metastatic Prostate Cancer Care?
CHICAGO — Prostate-specific antigen (PSA) levels could help guide treatment decisions for patients with metastatic hormone-sensitive prostate cancer, according to real-world findings from the IRONMAN study. Specifically, an undetectable PSA nadir — defined as PSA level < 0.2 ng/mL — predicted a good prognosis and a PSA level ≥ 0.2 ng/mL predicted poor prognosis among patients receiving androgen deprivation therapy (ADT) or androgen receptor pathway inhibitor (ARPI) therapy for 6-12 months, according to Michael Ong, MD, who presented the findings at the 2025 American Society of Clinical Oncology annual meeting. In other words, this real-world study found that absolute PSA at 6 and 12 months is prognostic in this patient population, said Ong, a medical oncologist at Ottawa Hospital Research Institute, Canada. Patients with a poor prognosis could then be considered for clinical trials offering therapy escalation, whereas those with a better prognosis — particularly those with PSA < 0.1 ng/mL — could be considered for de-escalation, said Ong. Ong explained that prior phase 3 studies have demonstrated that PSA > 0.2 ng/mL is associated with poor prognosis in patients receiving ADT and ARPI. However, data in real-world settings remain limited. Some patients with rapid PSA decline never progress, whereas others develop early resistance despite intensive therapy, he explained. The IRONMAN study set out to answer two main questions: When should PSA cutoffs be interpreted for prognostic significance? And how may PSA cutoffs differ in real-world patients? To this end, Ong and his colleagues included 1219 patients from the prospective IRONMAN cohort with metastatic hormone-sensitive prostate cancer who had received ADT and ARPI therapy, with or without docetaxel, and had PSA data available. PSA was stratified into three groups: ≥ 0.2 ng/mL, 0.10-0.19 ng/mL, and < 0.10 ng/mL. The research team constructed a 12-month landmark population to assess conditional overall survival (OS) and progression-free survival (PFS) at 6 and 12 months across each PSA level. The 12-month analysis was the primary study outcome. Patients were a median age of 70 years, 58% had Gleason score of 8-10, and 75% had de novo metastatic disease. Overall, most (74%) were White and just over half were enrolled from centers outside US or Canada. ARPI agents included abiraterone acetate (44%), apalutamide (21%), enzalutamide (22%), or darolutamide (13%), and 12% of patients received docetaxel in addition to doublet therapy with ADT plus ARPI. PSA levels shifted across the two time points. At 6 months, 52% of patients had a PSA < 0.2 ng/mL, whereas 48% had a PSA level ≥ 0.2 ng/mL. At 12 months, 68% had PSA levels < 0.2 ng/mL and 32% had levels ≥ 0.2 ng/mL. Both the 6- and 12-month landmark analyses showed that PSA ≥ 0.2 ng/mL was associated with worse conditional OS and PFS compared with PSA < 0.2 ng/mL. Ong broke down conditional OS and PFS at 12 months — the primary study outcome —by absolute PSA levels. Absolute PSA 3-year overall survival 3-year progression-free survival OS mortality risk (adjusted hazard ratio) ≥ 0.2 ng/mL 45% 41% 4.85 (3.36-7.01) 0.10-0.19 ng/mL 79% 62% 1.34 (0.82-2.20) < 0.1 ng/mL 84% 80% Reference After adjustment for confounders, PSA ≥ 0.2 ng/mL was associated with an almost fivefold higher risk for death at 12 months (adjusted hazard ratio, 4.85). Ong noted that PSA was prognostic of overall survival regardless of ARPI class or whether patients received doublet or triplet therapy with docetaxel. Invited discussant Rahul Aggarwal, MD, agreed that a PSA nadir between 6 and 12 months 'is strongly prognostic for progression-free and overall survival.' However, Aggarwal cautioned, although 'it is tempting to use PSA nadir to guide treatment decisions in clinical practice,' the approach has not been validated. Plus, other factors and biomarkers may play a role in treatment decisions and help optimize outcomes, including quality of life, treatment and financial toxicity, and the role of the tumor suppressor gene PTEN , added Aggarwal, of the University of California, San Francisco. 'We await randomized trial data to know, in fact, whether we should use this to guide treatment decision-making,' said Aggarwal. Such trials are underway. Ong is co-chair of a phase 3 study assessing survival after treatment escalation for patients with PSA ≥ 0.2 ng/mL after 6-12 months of ADT and ARPI therapy. Another phase 3 study will assess treatment de-escalation in those with PSA ≤ 0.2 ng/mL at 6-12 months after treatment initiation. This study's principal funder was the Movember Foundation; the Prostate Cancer Clinical Trials Consortium was a trial sponsor, plus Amgen, Astellas, AstraZeneca, Bayer, Janssen, Merck, Novartis and Sanofi provided funding support. Ong disclosed relationships with AstraZeneca, Bayer, Bristol-Myers Squibb, EMD Serono, Janssen, Merck, Novartis/AAA, Pfizer, Sanofi, and Ipsen. Aggarwal disclosed relationships with Alessa Therapeutics, Amgen, AstraZeneca, Bayer, BioXcel Therapeutics, Boxer Capital, Curio Science, and others.
Medscape
40 minutes ago
- Medscape
RCGP Urges Support to Save Declining GP Partnership Model
The Royal College of General Practitioners (RCGP) has warned that GP partnerships are under threat, as the number of partners in England has dropped by 25% over the past decade. In a new report, the college urged action to 'break down barriers to partnership' and called for modernisation of the model to make it more attractive to younger doctors. While the RCGP reaffirmed its support for the independent contractor model, it said there was 'room for modernisation and innovation', and backed ' a mixed economy' of contractual models to deliver general practice. Shift in Workforce Between 2015 and 2025, the number of GP partners in England fell from 24,491 to 18,367. Over the same period, the number of salaried GPs rose by 81%, from 10,270 in September 2015 to 18,557 in December 2024. As of June 2024, GP partners were a minority among fully qualified GPs for the first time. The most significant drop in partnership was seen in younger doctors. Among GPs aged 30-34, numbers fell by 72.9%. The only age group to show growth was those aged 60-64, up by 19.5%. Barriers to Partnership Rising workload, administrative burdens, and concerns about financial risk were cited as major deterrents to partnership. Professor Kamila Hawthorne, RCGP chair, said that many GPs were discouraged by the unlimited personal liability that comes with being a partner. She also pointed to the responsibilities of owning or leasing premises and managing staff, especially as patient demand increases. Exploring Alternatives The RCGP report explored alternative business models that could support general practice, including limited companies, limited liability partnerships (LLPs), and community benefit societies. The college maintained that partnerships still offered flexibility and potential for innovation, particularly if financial and workload pressures could be reduced. In 2024, more than half (55%) of RCGP members said they would be more likely to consider partnership if financial risks were lower. A review by Lord Darzi highlighted the financial discipline of GP partnerships, noting that they could not run large deficits like other parts of the NHS. Earlier this year, the Nuffield Trust described the current GP partnership model as 'withering'. The health think tank warned that the government's plans to improve GP access were at risk due to the fall in partner numbers. Thea Stein, chief executive of the Nuffield Trust, told Medscape News UK : 'It is hard to see partnership being the dominant model in the future.' She called for support where the model works well, but said new models must also be explored. Hawthorne maintained that 'there are elements of the traditional GP partnership that can be improved and modernised, while retaining its core strengths'. The GP partnership model has huge benefits for the NHS and for patients, she added. Government Response A Department of Health and Social Care (DHSC) spokesperson acknowledged the strengths of the partnership model, including efficiency, innovation, and continuity of care. 'However, we also recognise that this is not the only model delivering general practice,' the spokesperson told Medscape News UK . 'GP practices can choose to organise themselves in different ways and also provide good outcomes in terms of staff engagement and patient experience.'
